Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_assertion description "[Po-husk, apart from lowering LDL-C, also reduced TG, TG related to certain gene variants, TC, Apo B-100, oxLDL, insulin-resistance and systolic BP in mild-moderate hypercholesterolaemic individuals. Thus, the target patients to receive Po-husk would be those who present a cluster of various CVD risk factors, such as metabolic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_assertion evidence source_evidence_literature NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_assertion SIO_000772 20413122 NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_assertion wasDerivedFrom gad-20130706 NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_assertion wasGeneratedBy ECO_0000203 NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.
- gad-20130706 importedOn "2013-07-06" NP49734.RAVgWk0TZj5wExrEoXX6bF-jpWQFp6pk0PozGrD-nzViU130_provenance.